drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00319 | DB09293 | 790 | 116 | [
"DDInter1474",
"DDInter954"
] | Piperacillin | Iodide I-131 | Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
790,
24,
116
]
],
[
[
790,
1,
1249
],
[
1249,
24,
116
]
],
[
[
790,
24,
126
],
[
126,
24,
116
]
],
[
[
790,
40,
950
],
[
950,
24... | [
[
[
"Piperacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Piperacillin",
"{u} (Compound) resembles {v} (Compound)",
"Nafcillin"
],
[
"Nafcillin",
"{u} may cause a mod... | Piperacillin (Compound) resembles Nafcillin (Compound) and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Piperacillin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could... |
DB00261 | DB00757 | 702 | 1,166 | [
"DDInter93",
"DDInter581"
] | Anagrelide | Dolasetron | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
702,
25,
1166
]
],
[
[
702,
21,
28803
],
[
28803,
60,
1166
]
],
[
[
702,
24,
752
],
[
752,
23,
1166
]
],
[
[
702,
24,
463
],
[
463,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Anaemia"
],
[
"Anaemia",
"{u} (Side Effect) is caused by {v} (Compound... | Anagrelide (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Dolasetron (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Dolasetron
An... |
DB01234 | DB06589 | 1,220 | 1,250 | [
"DDInter513",
"DDInter1400"
] | Dexamethasone | Pazopanib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1220,
24,
1250
]
],
[
[
1220,
10,
11570
],
[
11570,
44,
1250
]
],
[
[
1220,
6,
3486
],
[
3486,
45,
1250
]
],
[
[
1220,
18,
17136
],
[
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Dexamethasone",
"{u} (Compound) palliates {v} (Disease)",
"kidney cancer"
],
[
"kidney cancer",
"{u} (Disease)... | Dexamethasone (Compound) palliates kidney cancer (Disease) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Dexamethasone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pazopanib (Compound)
Dexamethasone (Compound) downregulates SH2B3 (Gene) and SH2B3 (Gene) is bound by Pazopanib (Compound)
... |
DB00438 | DB00994 | 149 | 361 | [
"DDInter330",
"DDInter1277"
] | Ceftazidime | Neomycin | Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of esse... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Moderate | 1 | [
[
[
149,
24,
361
]
],
[
[
149,
21,
28722
],
[
28722,
60,
361
]
],
[
[
149,
24,
1132
],
[
1132,
24,
361
]
],
[
[
149,
24,
1448
],
[
1448,
... | [
[
[
"Ceftazidime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
]
],
[
[
"Ceftazidime",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by ... | Ceftazidime (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Neomycin (Compound)
Ceftazidime may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Ceft... |
DB00907 | DB09082 | 290 | 659 | [
"DDInter427",
"DDInter1934"
] | Cocaine (topical) | Vilanterol | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Major | 2 | [
[
[
290,
25,
659
]
],
[
[
290,
64,
895
],
[
895,
24,
659
]
],
[
[
290,
25,
1161
],
[
1161,
24,
659
]
],
[
[
290,
24,
1375
],
[
1375,
... | [
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylphenidate"
],
[
"Methylphenidate",
"{... | Cocaine may lead to a major life threatening interaction when taken with Vilanterol
Cocaine may lead to a major life threatening interaction when taken with Methylphenidate and Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Cocaine may lead to a major life thr... |
DB08824 | DB09128 | 591 | 1,241 | [
"DDInter959",
"DDInter231"
] | Ioflupane I-123 | Brexpiprazole | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
591,
24,
1241
]
],
[
[
591,
63,
222
],
[
222,
24,
1241
]
],
[
[
591,
63,
593
],
[
593,
25,
1241
]
],
[
[
591,
63,
222
],
[
222,
... | [
[
[
"Ioflupane I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Ioflupane I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
... | Ioflupane I-123 may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Ioflupane I-123 may cause a moderate interaction that could exacerbate diseases when taken with Buprop... |
DB00675 | DB11932 | 888 | 327 | [
"DDInter1744",
"DDInter3"
] | Tamoxifen | Abametapir (topical) | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
888,
24,
327
]
],
[
[
888,
24,
124
],
[
124,
63,
327
]
],
[
[
888,
25,
283
],
[
283,
63,
327
]
],
[
[
888,
63,
79
],
[
79,
24,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Tamoxifen may ... |
DB00204 | DB09039 | 228 | 1,670 | [
"DDInter580",
"DDInter629"
] | Dofetilide | Eliglustat | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
228,
25,
1670
]
],
[
[
228,
25,
322
],
[
322,
24,
1670
]
],
[
[
228,
25,
124
],
[
124,
63,
1670
]
],
[
[
228,
24,
597
],
[
597,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} m... | Dofetilide may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Dofetilide may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate intera... |
DB00472 | DB01105 | 758 | 222 | [
"DDInter758",
"DDInter1665"
] | Fluoxetine | Sibutramine | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
758,
25,
222
]
],
[
[
758,
6,
8374
],
[
8374,
45,
222
]
],
[
[
758,
21,
28737
],
[
28737,
60,
222
]
],
[
[
758,
63,
600
],
[
600,
... | [
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sibutr... | Fluoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Fluoxetine (Compound) causes Bursitis (Side Effect) and Bursitis (Side Effect) is caused by Sibutramine (Compound)
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flu... |
DB00108 | DB11817 | 1,066 | 1,259 | [
"DDInter1268",
"DDInter165"
] | Natalizumab | Baricitinib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1066,
25,
1259
]
],
[
[
1066,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
1066,
24,
949
],
[
949,
24,
1259
]
],
[
[
1066,
24,
1129
],
[
1129... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc ... | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium te... |
DB00374 | DB01105 | 1,061 | 222 | [
"DDInter1852",
"DDInter1665"
] | Treprostinil | Sibutramine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1061,
24,
222
]
],
[
[
1061,
18,
8386
],
[
8386,
57,
222
]
],
[
[
1061,
21,
29215
],
[
29215,
60,
222
]
],
[
[
1061,
24,
122
],
[
122,... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Treprostinil",
"{u} (Compound) downregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is downregulate... | Treprostinil (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Sibutramine (Compound)
Treprostinil (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Sibutramine (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when take... |
DB00477 | DB01176 | 216 | 537 | [
"DDInter363",
"DDInter453"
] | Chlorpromazine | Cyclizine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
216,
24,
537
]
],
[
[
216,
24,
1511
],
[
1511,
63,
537
]
],
[
[
216,
63,
1242
],
[
1242,
24,
537
]
],
[
[
216,
35,
104
],
[
104,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine a... |
DB00800 | DB01169 | 572 | 57 | [
"DDInter720",
"DDInter120"
] | Fenoldopam | Arsenic trioxide | A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
572,
25,
57
]
],
[
[
572,
63,
167
],
[
167,
25,
57
]
],
[
[
572,
24,
820
],
[
820,
64,
57
]
],
[
[
572,
24,
1264
],
[
1264,
25,
... | [
[
[
"Fenoldopam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"... | Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may lead to a major life threatening interaction when taken with Arsenic trioxide
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimem... |
DB00008 | DB08870 | 491 | 850 | [
"DDInter1407",
"DDInter228"
] | Peginterferon alfa-2a | Brentuximab vedotin | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
491,
24,
850
]
],
[
[
491,
24,
788
],
[
788,
24,
850
]
],
[
[
491,
25,
1477
],
[
1477,
24,
850
]
],
[
[
491,
24,
1468
],
[
1468,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with T... |
DB01114 | DB01233 | 272 | 1,311 | [
"DDInter362",
"DDInter1197"
] | Chlorpheniramine | Metoclopramide | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
272,
24,
1311
]
],
[
[
272,
6,
12523
],
[
12523,
45,
1311
]
],
[
[
272,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
272,
63,
1020
],
[
102... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by ... | Chlorpheniramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoclopramide (Compound)
Chlorpheniramine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when ta... |
DB01254 | DB12825 | 1,213 | 1,375 | [
"DDInter484",
"DDInter1032"
] | Dasatinib | Lefamulin | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
1213,
25,
1375
]
],
[
[
1213,
62,
112
],
[
112,
23,
1375
]
],
[
[
1213,
24,
159
],
[
159,
63,
1375
]
],
[
[
1213,
24,
309
],
[
309,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Dasatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Dasatinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Laro... |
DB00270 | DB09036 | 1,428 | 812 | [
"DDInter993",
"DDInter1668"
] | Isradipine | Siltuximab | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
1428,
24,
812
]
],
[
[
1428,
1,
1081
],
[
1081,
24,
812
]
],
[
[
1428,
24,
259
],
[
259,
24,
812
]
],
[
[
1428,
23,
467
],
[
467,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Isradipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a moder... | Isradipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that cou... |
DB00762 | DB13179 | 613 | 68 | [
"DDInter973",
"DDInter1882"
] | Irinotecan | Troleandomycin | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
613,
25,
68
]
],
[
[
613,
63,
1101
],
[
1101,
23,
68
]
],
[
[
613,
24,
1374
],
[
1374,
23,
68
]
],
[
[
613,
24,
1662
],
[
1662,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexaro... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abi... |
DB00595 | DB00900 | 1,545 | 45 | [
"DDInter1374",
"DDInter544"
] | Oxytetracycline | Didanosine | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Minor | 0 | [
[
[
1545,
23,
45
]
],
[
[
1545,
6,
10612
],
[
10612,
45,
45
]
],
[
[
1545,
40,
1620
],
[
1620,
23,
45
]
],
[
[
1545,
40,
1669
],
[
1669,
... | [
[
[
"Oxytetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Didanosine"
]
],
[
[
"Oxytetracycline",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (C... | Oxytetracycline (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Didanosine (Compound)
Oxytetracycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Didanosine
Oxytetracycline (Compound) resembles Minocycline (Co... |
DB00334 | DB01169 | 867 | 57 | [
"DDInter1326",
"DDInter120"
] | Olanzapine | Arsenic trioxide | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Moderate | 1 | [
[
[
867,
24,
57
]
],
[
[
867,
6,
8374
],
[
8374,
45,
57
]
],
[
[
867,
23,
112
],
[
112,
23,
57
]
],
[
[
867,
24,
480
],
[
480,
24,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Olanzapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Olan... |
DB00708 | DB09074 | 1,454 | 1,362 | [
"DDInter1718",
"DDInter1327"
] | Sufentanil | Olaparib | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1454,
24,
1362
]
],
[
[
1454,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
1454,
1,
1322
],
[
1322,
24,
1362
]
],
[
[
1454,
24,
1619
],
[
161... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
... | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sufentanil (Compound) resembles Alfentanil (Compound) and Alfentanil may cause a moderate interaction that could... |
DB01135 | DB01172 | 648 | 416 | [
"DDInter590",
"DDInter1004"
] | Doxacurium | Kanamycin | Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Major | 2 | [
[
[
648,
25,
416
]
],
[
[
648,
63,
608
],
[
608,
23,
416
]
],
[
[
648,
63,
91
],
[
91,
24,
416
]
],
[
[
648,
63,
1441
],
[
1441,
25,... | [
[
[
"Doxacurium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
]
],
[
[
"Doxacurium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Doxacurium may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Doxacurium may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin ... |
DB00285 | DB01166 | 1,100 | 477 | [
"DDInter1927",
"DDInter379"
] | Venlafaxine | Cilostazol | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1100,
24,
477
]
],
[
[
1100,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1100,
21,
28919
],
[
28919,
60,
477
]
],
[
[
1100,
23,
112
],
[
112,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Venlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Venlafaxine (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB00196 | DB00950 | 600 | 1,413 | [
"DDInter743",
"DDInter732"
] | Fluconazole | Fexofenadine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Minor | 0 | [
[
[
600,
23,
1413
]
],
[
[
600,
25,
1568
],
[
1568,
1,
1413
]
],
[
[
600,
24,
194
],
[
194,
40,
1413
]
],
[
[
600,
24,
543
],
[
543,
... | [
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fexofenadine"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
],
[
"Pimozide",... | Fluconazole may lead to a major life threatening interaction when taken with Pimozide and Pimozide (Compound) resembles Fexofenadine (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Fexofenadine (Compound)
Fluconazole... |
DB01224 | DB11827 | 623 | 433 | [
"DDInter1553",
"DDInter669"
] | Quetiapine | Ertugliflozin | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
623,
24,
433
]
],
[
[
623,
40,
695
],
[
695,
24,
433
]
],
[
[
623,
63,
959
],
[
959,
24,
433
]
],
[
[
623,
24,
820
],
[
820,
24,... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a modera... | Quetiapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could ... |
DB01132 | DB12825 | 1,130 | 1,375 | [
"DDInter1472",
"DDInter1032"
] | Pioglitazone | Lefamulin | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1130,
24,
1375
]
],
[
[
1130,
24,
159
],
[
159,
63,
1375
]
],
[
[
1130,
63,
966
],
[
966,
24,
1375
]
],
[
[
1130,
24,
659
],
[
659,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Octreotide a... |
DB00653 | DB01115 | 544 | 336 | [
"DDInter1120",
"DDInter1291"
] | Magnesium sulfate | Nifedipine | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
544,
24,
336
]
],
[
[
544,
63,
1428
],
[
1428,
1,
336
]
],
[
[
544,
63,
1081
],
[
1081,
40,
336
]
],
[
[
544,
24,
409
],
[
409,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedi... |
DB11110 | DB11943 | 603 | 255 | [
"DDInter1115",
"DDInter495"
] | Magnesium citrate | Delafloxacin | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
603,
24,
255
]
],
[
[
603,
63,
613
],
[
613,
23,
255
]
],
[
[
603,
24,
913
],
[
913,
24,
255
]
],
[
[
603,
24,
971
],
[
971,
63,... | [
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"... | Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Apaluta... |
DB00395 | DB01233 | 210 | 1,311 | [
"DDInter301",
"DDInter1197"
] | Carisoprodol | Metoclopramide | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
210,
24,
1311
]
],
[
[
210,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
210,
24,
649
],
[
649,
63,
1311
]
],
[
[
210,
24,
662
],
[
662,
... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Carisoprodol",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effec... | Carisoprodol (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00384 | DB01276 | 1,275 | 123 | [
"DDInter1859",
"DDInter706"
] | Triamterene | Exenatide | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1275,
24,
123
]
],
[
[
1275,
24,
708
],
[
708,
63,
123
]
],
[
[
1275,
24,
1573
],
[
1573,
24,
123
]
],
[
[
1275,
63,
999
],
[
999,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and... |
DB00261 | DB00697 | 702 | 876 | [
"DDInter93",
"DDInter1821"
] | Anagrelide | Tizanidine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Major | 2 | [
[
[
702,
25,
876
]
],
[
[
702,
6,
7950
],
[
7950,
45,
876
]
],
[
[
702,
7,
2384
],
[
2384,
46,
876
]
],
[
[
702,
18,
6718
],
[
6718,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
]
],
[
[
"Anagrelide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tizanid... | Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Anagrelide (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Tizanidine (Compound)
Anagrelide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Tizanidine (Compound)
Anagrelide (Comp... |
DB00176 | DB11581 | 529 | 1,456 | [
"DDInter770",
"DDInter1926"
] | Fluvoxamine | Venetoclax | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
529,
24,
1456
]
],
[
[
529,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
529,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
529,
24,
86
],
[
86,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib... |
DB00851 | DB01101 | 611 | 60 | [
"DDInter463",
"DDInter285"
] | Dacarbazine | Capecitabine | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
611,
24,
60
]
],
[
[
611,
23,
872
],
[
872,
62,
60
]
],
[
[
611,
62,
1176
],
[
1176,
23,
60
]
],
[
[
611,
23,
246
],
[
246,
23,
... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Dacarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
... | Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Mo... |
DB01601 | DB09078 | 833 | 1,228 | [
"DDInter1089",
"DDInter1036"
] | Lopinavir | Lenvatinib | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to ... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
833,
24,
1228
]
],
[
[
833,
63,
770
],
[
770,
24,
1228
]
],
[
[
833,
24,
603
],
[
603,
63,
1228
]
],
[
[
833,
24,
1374
],
[
1374,
... | [
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lopinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
... | Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and... |
DB00357 | DB08881 | 1,051 | 868 | [
"DDInter71",
"DDInter1925"
] | Aminoglutethimide | Vemurafenib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1051,
24,
868
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1051,
18,
20102
],
[
20102,
57,
868
]
],
[
[
1051,
21,
29106
],
[
291... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Aminoglutethimide (Compound) downregulates FAM57A (Gene) and FAM57A (Gene) is downregulated by Vemurafenib (Compound)
Aminoglutethimide (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vem... |
DB01124 | DB11255 | 1,411 | 1,371 | [
"DDInter1828",
"DDInter374"
] | Tolbutamide | Chromium picolinate | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Moderate | 1 | [
[
[
1411,
24,
1371
]
],
[
[
1411,
1,
245
],
[
245,
24,
1371
]
],
[
[
1411,
24,
5
],
[
5,
24,
1371
]
],
[
[
1411,
63,
1645
],
[
1645,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Tolbutamide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may ca... | Tolbutamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interac... |
DB00748 | DB14740 | 662 | 771 | [
"DDInter297",
"DDInter881"
] | Carbinoxamine | Hyaluronidase | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permea... | Minor | 0 | [
[
[
662,
23,
771
]
],
[
[
662,
35,
849
],
[
849,
23,
771
]
],
[
[
662,
24,
337
],
[
337,
23,
771
]
],
[
[
662,
63,
1242
],
[
1242,
2... | [
[
[
"Carbinoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when ... | Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Carbinoxamine may cause a moderate interaction ... |
DB01177 | DB01236 | 77 | 679 | [
"DDInter904",
"DDInter1664"
] | Idarubicin | Sevoflurane | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
77,
24,
679
]
],
[
[
77,
63,
1262
],
[
1262,
40,
679
]
],
[
[
77,
21,
28751
],
[
28751,
60,
679
]
],
[
[
77,
62,
112
],
[
112,
2... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Idarubicin (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Sevoflurane (Compound)
Idarubicin may cause a minor interaction... |
DB06688 | DB11730 | 1,430 | 351 | [
"DDInter1677",
"DDInter1588"
] | Sipuleucel-T | Ribociclib | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1430,
24,
351
]
],
[
[
1430,
24,
310
],
[
310,
24,
351
]
],
[
[
1430,
63,
1532
],
[
1532,
24,
351
]
],
[
[
1430,
24,
738
],
[
738,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and ... |
DB06210 | DB08870 | 72 | 850 | [
"DDInter631",
"DDInter228"
] | Eltrombopag | Brentuximab vedotin | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
72,
24,
850
]
],
[
[
72,
24,
788
],
[
788,
24,
850
]
],
[
[
72,
63,
671
],
[
671,
24,
850
]
],
[
[
72,
24,
1033
],
[
1033,
63,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Fluvas... |
DB01246 | DB01263 | 820 | 859 | [
"DDInter45",
"DDInter1494"
] | Alimemazine | Posaconazole | A phenothiazine derivative that is used as an antipruritic. | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
820,
24,
859
]
],
[
[
820,
6,
8374
],
[
8374,
45,
859
]
],
[
[
820,
21,
28680
],
[
28680,
60,
859
]
],
[
[
820,
62,
112
],
[
112,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Alimemazine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Posaconazole (Compound)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metron... |
DB11988 | DB15762 | 270 | 725 | [
"DDInter1321",
"DDInter1644"
] | Ocrelizumab | Satralizumab | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
270,
24,
725
]
],
[
[
270,
62,
1193
],
[
1193,
23,
725
]
],
[
[
270,
63,
1362
],
[
1362,
24,
725
]
],
[
[
270,
64,
1066
],
[
1066,
... | [
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Ocrelizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
... | Ocrelizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and ... |
DB00197 | DB14723 | 1,324 | 159 | [
"DDInter1881",
"DDInter1026"
] | Troglitazone | Larotrectinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1324,
24,
159
]
],
[
[
1324,
24,
222
],
[
222,
23,
159
]
],
[
[
1324,
23,
271
],
[
271,
23,
159
]
],
[
[
1324,
24,
1375
],
[
1375,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Mirabegron and M... |
DB00250 | DB01229 | 10 | 973 | [
"DDInter475",
"DDInter1377"
] | Dapsone | Paclitaxel | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
10,
24,
973
]
],
[
[
10,
24,
310
],
[
310,
63,
973
]
],
[
[
10,
6,
7524
],
[
7524,
45,
973
]
],
[
[
10,
18,
4930
],
[
4930,
57,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Dapsone (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Dapsone (Compound) dow... |
DB00359 | DB00704 | 161 | 267 | [
"DDInter1721",
"DDInter1263"
] | Sulfadiazine | Naltrexone | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
161,
24,
267
]
],
[
[
161,
21,
28787
],
[
28787,
60,
267
]
],
[
[
161,
24,
850
],
[
850,
63,
267
]
],
[
[
161,
1,
50
],
[
50,
63... | [
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) i... | Sulfadiazine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Naltrexone (Compound)
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases... |
DB11943 | DB11986 | 255 | 484 | [
"DDInter495",
"DDInter648"
] | Delafloxacin | Entrectinib | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
255,
24,
484
]
],
[
[
255,
24,
466
],
[
466,
62,
484
]
],
[
[
255,
62,
322
],
[
322,
24,
484
]
],
[
[
255,
24,
1320
],
[
1320,
2... | [
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Epirubicin and E... |
DB06626 | DB12887 | 263 | 1,598 | [
"DDInter147",
"DDInter1750"
] | Axitinib | Tazemetostat | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
263,
24,
1598
]
],
[
[
263,
62,
752
],
[
752,
24,
1598
]
],
[
[
263,
63,
1324
],
[
1324,
24,
1598
]
],
[
[
263,
24,
578
],
[
578,
... | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Axitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
... | Axitinib may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglita... |
DB00472 | DB06704 | 758 | 247 | [
"DDInter758",
"DDInter951"
] | Fluoxetine | Iobenguane (I-123) | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
758,
24,
247
]
],
[
[
758,
6,
7390
],
[
7390,
45,
247
]
],
[
[
758,
21,
28787
],
[
28787,
60,
247
]
],
[
[
758,
24,
820
],
[
820,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Fluoxetine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Fluoxetine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Fluoxe... |
DB00726 | DB04843 | 1,164 | 1,511 | [
"DDInter1876",
"DDInter1149"
] | Trimipramine | Mepenzolate | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1164,
24,
1511
]
],
[
[
1164,
1,
675
],
[
675,
24,
1511
]
],
[
[
1164,
24,
537
],
[
537,
24,
1511
]
],
[
[
1164,
63,
352
],
[
352,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u... | Trimipramine (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate int... |
DB04951 | DB15982 | 187 | 1,339 | [
"DDInter1477",
"DDInter193"
] | Pirfenidone | Berotralstat | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
187,
24,
1339
]
],
[
[
187,
24,
283
],
[
283,
23,
1339
]
],
[
[
187,
24,
39
],
[
39,
24,
1339
]
],
[
[
187,
63,
300
],
[
300,
24... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Pa... |
DB01114 | DB01209 | 272 | 1,359 | [
"DDInter362",
"DDInter531"
] | Chlorpheniramine | Dezocine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
272,
24,
1359
]
],
[
[
272,
63,
234
],
[
234,
1,
1359
]
],
[
[
272,
63,
717
],
[
717,
24,
1359
]
],
[
[
272,
74,
1594
],
[
1594,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moder... |
DB01110 | DB01764 | 86 | 805 | [
"DDInter1209",
"DDInter469"
] | Miconazole | Dalfopristin | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
86,
24,
805
]
],
[
[
86,
6,
8374
],
[
8374,
45,
805
]
],
[
[
86,
62,
222
],
[
222,
23,
805
]
],
[
[
86,
23,
466
],
[
466,
62,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Miconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Miconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Miconazole may c... |
DB01132 | DB06717 | 1,130 | 875 | [
"DDInter1472",
"DDInter778"
] | Pioglitazone | Fosaprepitant | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
1130,
24,
875
]
],
[
[
1130,
63,
723
],
[
723,
1,
875
]
],
[
[
1130,
21,
29122
],
[
29122,
60,
875
]
],
[
[
1130,
63,
222
],
[
222,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Pioglitazone (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Fosaprepitant (Compound)
Pioglitazone... |
DB01155 | DB09045 | 872 | 52 | [
"DDInter813",
"DDInter607"
] | Gemifloxacin | Dulaglutide | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
872,
24,
52
]
],
[
[
872,
24,
170
],
[
170,
23,
52
]
],
[
[
872,
24,
609
],
[
609,
24,
52
]
],
[
[
872,
40,
1467
],
[
1467,
24,
... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin a... |
DB01284 | DB06372 | 1,042 | 259 | [
"DDInter1782",
"DDInter1594"
] | Tetracosactide | Rilonacept | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
1042,
24,
259
]
],
[
[
1042,
24,
1367
],
[
1367,
63,
259
]
],
[
[
1042,
63,
409
],
[
409,
24,
259
]
],
[
[
1042,
24,
4
],
[
4,
2... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant) and Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Tetracosactide may cause a moderate interaction that could exa... |
DB04896 | DB04932 | 901 | 1,564 | [
"DDInter1220",
"DDInter491"
] | Milnacipran | Defibrotide | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Moderate | 1 | [
[
[
901,
24,
1564
]
],
[
[
901,
64,
1039
],
[
1039,
24,
1564
]
],
[
[
901,
63,
714
],
[
714,
24,
1564
]
],
[
[
901,
40,
41
],
[
41,
... | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Milnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"De... | Milnacipran may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost m... |
DB00373 | DB00424 | 461 | 19 | [
"DDInter1809",
"DDInter896"
] | Timolol | Hyoscyamine | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Moderate | 1 | [
[
[
461,
24,
19
]
],
[
[
461,
25,
1166
],
[
1166,
1,
19
]
],
[
[
461,
24,
85
],
[
85,
63,
19
]
],
[
[
461,
21,
29093
],
[
29093,
60,... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
... | Timolol may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron (Compound) resembles Hyoscyamine (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases whe... |
DB01165 | DB11126 | 1,539 | 900 | [
"DDInter1325",
"DDInter276"
] | Ofloxacin | Calcium gluconate | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
1539,
24,
900
]
],
[
[
1539,
1,
945
],
[
945,
24,
900
]
],
[
[
1539,
40,
1176
],
[
1176,
24,
900
]
],
[
[
1539,
1,
945
],
[
945,
... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause ... | Ofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Ofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00843 | DB11901 | 479 | 913 | [
"DDInter583",
"DDInter107"
] | Donepezil | Apalutamide | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
479,
24,
913
]
],
[
[
479,
24,
112
],
[
112,
23,
913
]
],
[
[
479,
62,
600
],
[
600,
24,
913
]
],
[
[
479,
63,
485
],
[
485,
24,... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Donepezil may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluc... |
DB01234 | DB15091 | 1,220 | 676 | [
"DDInter513",
"DDInter1901"
] | Dexamethasone | Upadacitinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1220,
25,
676
]
],
[
[
1220,
23,
1193
],
[
1193,
23,
676
]
],
[
[
1220,
62,
1461
],
[
1461,
23,
676
]
],
[
[
1220,
24,
1430
],
[
1430,... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vitamin E a... |
DB00637 | DB01159 | 1,557 | 419 | [
"DDInter128",
"DDInter854"
] | Astemizole | Halothane | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Moderate | 1 | [
[
[
1557,
24,
419
]
],
[
[
1557,
6,
8374
],
[
8374,
45,
419
]
],
[
[
1557,
23,
112
],
[
112,
23,
419
]
],
[
[
1557,
24,
629
],
[
629,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Astemizole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halothane (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halothane
Astemizole may cau... |
DB00502 | DB14723 | 1,300 | 159 | [
"DDInter853",
"DDInter1026"
] | Haloperidol | Larotrectinib | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1300,
24,
159
]
],
[
[
1300,
24,
222
],
[
222,
23,
159
]
],
[
[
1300,
24,
741
],
[
741,
24,
159
]
],
[
[
1300,
40,
78
],
[
78,
2... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and R... |
DB00726 | DB06589 | 1,164 | 1,250 | [
"DDInter1876",
"DDInter1400"
] | Trimipramine | Pazopanib | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1164,
24,
1250
]
],
[
[
1164,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
1164,
21,
28868
],
[
28868,
60,
1250
]
],
[
[
1164,
23,
112
],
[
11... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)"... | Trimipramine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Trimipramine (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Pazopanib (Compound)
Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and... |
DB00635 | DB00819 | 1,573 | 471 | [
"DDInter1515",
"DDInter15"
] | Prednisone | Acetazolamide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Moderate | 1 | [
[
[
1573,
24,
471
]
],
[
[
1573,
24,
997
],
[
997,
40,
471
]
],
[
[
1573,
6,
8374
],
[
8374,
45,
471
]
],
[
[
1573,
21,
29232
],
[
29232,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
],
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Prednisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Acetazolamide (Compound)
Prednisone (Compound) causes Urticaria (Side Effect) a... |
DB00220 | DB01261 | 798 | 170 | [
"DDInter1276",
"DDInter1679"
] | Nelfinavir | Sitagliptin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
798,
24,
170
]
],
[
[
798,
6,
8374
],
[
8374,
45,
170
]
],
[
[
798,
21,
28850
],
[
28850,
60,
170
]
],
[
[
798,
24,
52
],
[
52,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Nelfinavir (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and D... |
DB00991 | DB08870 | 97 | 850 | [
"DDInter1358",
"DDInter228"
] | Oxaprozin | Brentuximab vedotin | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
97,
24,
850
]
],
[
[
97,
63,
267
],
[
267,
24,
850
]
],
[
[
97,
25,
1468
],
[
1468,
63,
850
]
],
[
[
97,
25,
39
],
[
39,
24,
... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Oxaprozin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may c... |
DB00333 | DB09104 | 576 | 286 | [
"DDInter1166",
"DDInter1118"
] | Methadone | Magnesium hydroxide | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
576,
24,
286
]
],
[
[
576,
36,
820
],
[
820,
23,
286
]
],
[
[
576,
24,
104
],
[
104,
23,
286
]
],
[
[
576,
1,
146
],
[
146,
23,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Methadone",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}"... | Methadone (Compound) resembles Alimemazine (Compound) and Methadone may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Methadone may cause a moderate interaction that could exacerb... |
DB00833 | DB08880 | 1,305 | 1,510 | [
"DDInter309",
"DDInter1771"
] | Cefaclor | Teriflunomide | Semisynthetic, broad-spectrum antibiotic derivative of cephalexin. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
1305,
24,
1510
]
],
[
[
1305,
63,
597
],
[
597,
24,
1510
]
],
[
[
1305,
24,
1096
],
[
1096,
25,
1510
]
],
[
[
1305,
63,
597
],
[
597,
... | [
[
[
"Cefaclor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cefaclor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
... | Cefaclor may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Cefaclor may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic... |
DB00842 | DB09293 | 686 | 116 | [
"DDInter1359",
"DDInter954"
] | Oxazepam | Iodide I-131 | Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feat... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
686,
24,
116
]
],
[
[
686,
63,
701
],
[
701,
24,
116
]
],
[
[
686,
24,
516
],
[
516,
24,
116
]
],
[
[
686,
40,
1418
],
[
1418,
2... | [
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Oxazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levo... |
DB01041 | DB10315 | 770 | 1,137 | [
"DDInter1789",
"DDInter1127"
] | Thalidomide | Measles virus vaccine live attenuated | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
770,
25,
1137
]
],
[
[
770,
64,
581
],
[
581,
25,
1137
]
],
[
[
770,
63,
1184
],
[
1184,
25,
1137
]
],
[
[
770,
24,
1491
],
[
1491,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
... | Thalidomide may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra ... |
DB00370 | DB00694 | 1,251 | 51 | [
"DDInter1230",
"DDInter485"
] | Mirtazapine | Daunorubicin | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
1251,
24,
51
]
],
[
[
1251,
6,
7950
],
[
7950,
45,
51
]
],
[
[
1251,
18,
10699
],
[
10699,
57,
51
]
],
[
[
1251,
21,
28972
],
[
28972,... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compoun... | Mirtazapine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound)
Mirtazapine (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Daunorubicin (Compound)
Mirtazapine (Compound) causes Urine output increased (Side Effect) and Urine output increased (Side Effect) is... |
DB01254 | DB05812 | 1,213 | 1,374 | [
"DDInter484",
"DDInter8"
] | Dasatinib | Abiraterone | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1213,
24,
1374
]
],
[
[
1213,
63,
1561
],
[
1561,
1,
1374
]
],
[
[
1213,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
1213,
21,
29113
],
[
291... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Abiraterone (Compound)
Dasatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Dasatinib (Compound) causes Hypokalaemia (Side Effect) and Hyp... |
DB01142 | DB11986 | 1,264 | 484 | [
"DDInter593",
"DDInter648"
] | Doxepin | Entrectinib | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1264,
24,
484
]
],
[
[
1264,
62,
1247
],
[
1247,
23,
484
]
],
[
[
1264,
24,
271
],
[
271,
23,
484
]
],
[
[
1264,
64,
222
],
[
222,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Doxepin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mir... |
DB00445 | DB11718 | 322 | 927 | [
"DDInter655",
"DDInter640"
] | Epirubicin | Encorafenib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
322,
24,
927
]
],
[
[
322,
23,
112
],
[
112,
23,
927
]
],
[
[
322,
24,
216
],
[
216,
24,
927
]
],
[
[
322,
24,
1399
],
[
1399,
6... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and... |
DB00938 | DB13074 | 455 | 877 | [
"DDInter1635",
"DDInter1110"
] | Salmeterol | Macimorelin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
455,
25,
877
]
],
[
[
455,
24,
673
],
[
673,
24,
877
]
],
[
[
455,
63,
176
],
[
176,
24,
877
]
],
[
[
455,
23,
1042
],
[
1042,
2... | [
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripipr... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine... |
DB00307 | DB00877 | 1,101 | 629 | [
"DDInter202",
"DDInter1678"
] | Bexarotene | Sirolimus | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1101,
24,
629
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
629
]
],
[
[
1101,
21,
29203
],
[
29203,
60,
629
]
],
[
[
1101,
24,
907
],
[
907,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sirolimus (Compound)
Bexarotene (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Bexarotene may cause a moderate interaction that could exa... |
DB00222 | DB00902 | 245 | 104 | [
"DDInter825",
"DDInter1168"
] | Glimepiride | Methdilazine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
245,
24,
104
]
],
[
[
245,
24,
820
],
[
820,
1,
104
]
],
[
[
245,
24,
401
],
[
401,
63,
104
]
],
[
[
245,
24,
286
],
[
286,
62,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction ... |
DB05679 | DB10989 | 1,683 | 496 | [
"DDInter1907",
"DDInter858"
] | Ustekinumab | Hepatitis A Vaccine | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1683,
24,
496
]
],
[
[
1683,
24,
1093
],
[
1093,
63,
496
]
],
[
[
1683,
63,
4
],
[
4,
24,
496
]
],
[
[
1683,
24,
850
],
[
850,
2... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxin... |
DB00280 | DB01142 | 494 | 1,264 | [
"DDInter575",
"DDInter593"
] | Disopyramide | Doxepin | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
494,
25,
1264
]
],
[
[
494,
25,
401
],
[
401,
24,
1264
]
],
[
[
494,
35,
832
],
[
832,
24,
1264
]
],
[
[
494,
1,
11439
],
[
11439,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"... | Disopyramide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Disopyramide (Compound) resembles Tripelennamine (Compound) and Disopyramide may cause a moderate interaction that could exa... |
DB00224 | DB01254 | 215 | 1,213 | [
"DDInter917",
"DDInter484"
] | Indinavir | Dasatinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
215,
25,
1213
]
],
[
[
215,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
215,
7,
4786
],
[
4786,
45,
1213
]
],
[
[
215,
7,
7245
],
[
7245,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
... | Indinavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Indinavir (Compound) upregulates EPHB2 (Gene) and EPHB2 (Gene) is bound by Dasatinib (Compound)
Indinavir (Compound) upregulates SSBP2 (Gene) and SSBP2 (Gene) is upregulated by Dasatinib (Compound)
Indinavir (Compound) downregulat... |
DB08822 | DB11921 | 911 | 1,019 | [
"DDInter156",
"DDInter492"
] | Azilsartan medoxomil | Deflazacort | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
911,
24,
1019
]
],
[
[
911,
63,
629
],
[
629,
24,
1019
]
],
[
[
911,
24,
1344
],
[
1344,
24,
1019
]
],
[
[
911,
40,
217
],
[
217,
... | [
[
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Azilsartan medoxomil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siroli... | Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Ca... |
DB00197 | DB01044 | 1,324 | 246 | [
"DDInter1881",
"DDInter809"
] | Troglitazone | Gatifloxacin | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Major | 2 | [
[
[
1324,
25,
246
]
],
[
[
1324,
24,
1176
],
[
1176,
1,
246
]
],
[
[
1324,
24,
872
],
[
872,
40,
246
]
],
[
[
1324,
24,
147
],
[
147,
... | [
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Mo... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Gatiflox... |
DB00041 | DB01173 | 1,648 | 358 | [
"DDInter38",
"DDInter1349"
] | Aldesleukin | Orphenadrine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1648,
24,
358
]
],
[
[
1648,
24,
820
],
[
820,
63,
358
]
],
[
[
1648,
24,
758
],
[
758,
40,
358
]
],
[
[
1648,
24,
1164
],
[
1164,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and ... |
DB00662 | DB01618 | 717 | 776 | [
"DDInter1873",
"DDInter1239"
] | Trimethobenzamide | Molindone | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
717,
24,
776
]
],
[
[
717,
21,
28691
],
[
28691,
60,
776
]
],
[
[
717,
24,
100
],
[
100,
24,
776
]
],
[
[
717,
24,
407
],
[
407,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Trimethobenzamide",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side ... | Trimethobenzamide (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Molindone (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate disease... |
DB00284 | DB00477 | 1,647 | 216 | [
"DDInter11",
"DDInter363"
] | Acarbose | Chlorpromazine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
1647,
24,
216
]
],
[
[
1647,
24,
1178
],
[
1178,
1,
216
]
],
[
[
1647,
24,
684
],
[
684,
40,
216
]
],
[
[
1647,
21,
28898
],
[
28898,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Chlorpro... |
DB00529 | DB12141 | 789 | 971 | [
"DDInter779",
"DDInter817"
] | Foscarnet | Gilteritinib | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
789,
24,
971
]
],
[
[
789,
23,
112
],
[
112,
23,
971
]
],
[
[
789,
25,
485
],
[
485,
24,
971
]
],
[
[
789,
24,
823
],
[
823,
63,... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Foscarnet",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Foscarnet may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may ca... |
DB01009 | DB01250 | 935 | 712 | [
"DDInter1009",
"DDInter1334"
] | Ketoprofen | Olsalazine | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
935,
24,
712
]
],
[
[
935,
1,
11346
],
[
11346,
40,
712
]
],
[
[
935,
63,
50
],
[
50,
40,
712
]
],
[
[
935,
40,
345
],
[
345,
1,... | [
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u}... | Ketoprofen (Compound) resembles Magnesium salicylate (Compound) and Magnesium salicylate (Compound) resembles Olsalazine (Compound)
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Ketoprofen (Compound) ... |
DB01396 | DB05829 | 1,482 | 391 | [
"DDInter553",
"DDInter1393"
] | Digitoxin | Parathyroid hormone | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a... | Major | 2 | [
[
[
1482,
25,
391
]
],
[
[
1482,
40,
1252
],
[
1252,
25,
391
]
],
[
[
1482,
18,
5795
],
[
5795,
46,
1485
],
[
1485,
24,
391
]
],
[
[
1482,... | [
[
[
"Digitoxin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Parathyroid hormone"
]
],
[
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} may lead to a major life threaten... | Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may lead to a major life threatening interaction when taken with Parathyroid hormone
Digitoxin (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is upregulated by Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could... |
DB00238 | DB09039 | 188 | 1,670 | [
"DDInter1285",
"DDInter629"
] | Nevirapine | Eliglustat | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
188,
24,
1670
]
],
[
[
188,
24,
1135
],
[
1135,
62,
1670
]
],
[
[
188,
24,
1409
],
[
1409,
24,
1670
]
],
[
[
188,
24,
1499
],
[
1499,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may... |
DB09074 | DB11760 | 1,362 | 119 | [
"DDInter1327",
"DDInter1742"
] | Olaparib | Talazoparib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1362,
24,
119
]
],
[
[
1362,
63,
66
],
[
66,
24,
119
]
],
[
[
1362,
64,
441
],
[
441,
24,
119
]
],
[
[
1362,
24,
1129
],
[
1129,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Olaparib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a... |
DB04843 | DB08815 | 1,511 | 154 | [
"DDInter1149",
"DDInter1104"
] | Mepenzolate | Lurasidone | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1511,
24,
154
]
],
[
[
1511,
21,
29118
],
[
29118,
60,
154
]
],
[
[
1511,
63,
100
],
[
100,
24,
154
]
],
[
[
1511,
40,
649
],
[
649,
... | [
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Mepenzolate",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) i... | Mepenzolate (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Lurasidone (Compound)
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when ta... |
DB00719 | DB00980 | 1,219 | 969 | [
"DDInter149",
"DDInter1564"
] | Azatadine | Ramelteon | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
1219,
24,
969
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
969
]
],
[
[
1219,
24,
100
],
[
100,
24,
969
]
],
[
[
1219,
63,
1242
],
[
1242,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Azatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Azatadine ma... |
DB00305 | DB00773 | 377 | 896 | [
"DDInter1232",
"DDInter702"
] | Mitomycin | Etoposide | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
377,
24,
896
]
],
[
[
377,
5,
11642
],
[
11642,
44,
896
]
],
[
[
377,
18,
3930
],
[
3930,
45,
896
]
],
[
[
377,
6,
4973
],
[
4973,
... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Mitomycin",
"{u} (Compound) treats {v} (Disease)",
"urinary bladder cancer"
],
[
"urinary bladder cancer",
"{u} (D... | Mitomycin (Compound) treats urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is treated by Etoposide (Compound)
Mitomycin (Compound) downregulates TOP2B (Gene) and TOP2B (Gene) is bound by Etoposide (Compound)
Mitomycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etoposide (Compound)... |
DB11703 | DB14723 | 405 | 159 | [
"DDInter9",
"DDInter1026"
] | Acalabrutinib | Larotrectinib | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
405,
24,
159
]
],
[
[
405,
63,
222
],
[
222,
23,
159
]
],
[
[
405,
24,
1375
],
[
1375,
24,
159
]
],
[
[
405,
63,
98
],
[
98,
24,... | [
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin an... |
DB00758 | DB08896 | 1,347 | 292 | [
"DDInter413",
"DDInter1576"
] | Clopidogrel | Regorafenib | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
1347,
25,
292
]
],
[
[
1347,
6,
6017
],
[
6017,
45,
292
]
],
[
[
1347,
7,
2637
],
[
2637,
45,
292
]
],
[
[
1347,
21,
29122
],
[
29122,... | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Clopidogrel",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Rego... | Clopidogrel (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Clopidogrel (Compound) upregulates FGFR2 (Gene) and FGFR2 (Gene) is bound by Regorafenib (Compound)
Clopidogrel (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Regoraf... |
DB06603 | DB11986 | 39 | 484 | [
"DDInter1387",
"DDInter648"
] | Panobinostat | Entrectinib | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
39,
25,
484
]
],
[
[
39,
62,
1247
],
[
1247,
23,
484
]
],
[
[
39,
64,
1539
],
[
1539,
24,
484
]
],
[
[
39,
25,
774
],
[
774,
24,... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Panobinostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Panobinostat may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin... |
DB01018 | DB09074 | 1,364 | 1,362 | [
"DDInter847",
"DDInter1327"
] | Guanfacine | Olaparib | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1364,
24,
1362
]
],
[
[
1364,
24,
1478
],
[
1478,
24,
1362
]
],
[
[
1364,
63,
353
],
[
353,
24,
1362
]
],
[
[
1364,
24,
1619
],
[
1619... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofu... |
DB00258 | DB01203 | 666 | 699 | [
"DDInter270",
"DDInter1255"
] | Calcium acetate | Nadolol | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
666,
24,
699
]
],
[
[
666,
24,
729
],
[
729,
1,
699
]
],
[
[
666,
21,
28722
],
[
28722,
60,
699
]
],
[
[
666,
24,
1152
],
[
1152,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Calcium acetate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Nadolol (Compound)
Calcium acetate may cause a moderate interacti... |
DB01035 | DB09156 | 1,401 | 777 | [
"DDInter1524",
"DDInter964"
] | Procainamide | Iopromide | A derivative of procaine with less CNS action. | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
1401,
24,
777
]
],
[
[
1401,
63,
1645
],
[
1645,
25,
777
]
],
[
[
1401,
64,
485
],
[
485,
25,
777
]
],
[
[
1401,
63,
1645
],
[
1645,
... | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
... | Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may lead to a major life threatening interaction when taken with Iopromide
Procainamide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major li... |
DB00242 | DB11921 | 1,064 | 1,019 | [
"DDInter392",
"DDInter492"
] | Cladribine | Deflazacort | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
1064,
25,
1019
]
],
[
[
1064,
63,
1461
],
[
1461,
23,
1019
]
],
[
[
1064,
25,
270
],
[
270,
63,
1019
]
],
[
[
1064,
24,
200
],
[
200,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Cladribine may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.